Repare Therapeutics Inc. Overview
Pro stress-test →Repare Therapeutics is a clinical-stage precision oncology company that uses its proprietary SNIPRx platform to discover and develop cancer therapies targeting genomic instability and DNA damage repair mechanisms. The company has strategic collaborations with major pharmaceutical partners including Roche, Bristol-Myers Squibb, and Ono Pharmaceutical.
Strategic Profile
Pro stress-test →As of January 16, 2026, Repare shareholders approved a plan of arrangement to be acquired by XenoTherapeutics with 99.76% of votes cast in favor. The company has monetized its portfolio through major licensing deals, including a worldwide agreement with Debiopharm for lunresertib worth up to $257 million in milestones, and out-licensed its discovery platforms to DCx Biotherapeutics receiving $1 million upfront and a 9.99% equity stake.
Competitive Landscape
Pro stress-test →Repare competes in the precision oncology space alongside companies developing synthetic lethal therapeutics and DNA damage repair inhibitors. Strategic partnerships with Roche, Bristol-Myers Squibb, Debiopharm, and academic institutions position Repare within an established biopharma ecosystem rather than as a direct competitor. The acquisition by XenoTherapeutics repositions the company within a non-profit research model.
Industry Context
Repare Therapeutics Inc. operates in Clinical-Stage Precision Oncology / Biotechnology.
Key facts
Founded: 2016 · Headquarters: Montreal, Canada · Employees: ~91 · Revenue: N/A · Market cap: $114.2M